Abstract
Aim/introduction: Prostate cancer is the most commonly diagnosed male cancer in the UK; one third of all new cases present with locally advanced disease. At UCLH, high risk patients deemed to benefit from dose escalation have been treated with combined EBRT and HDR brachytherapy boost since 2000. We revisited 32 of these patients to assess late bowel and bladder toxicity, survival, biochemical relapse and metastatic disease rates.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
